ZimVie initiated with a Buy at B. Riley

B. Riley analyst Anderson Schock last night initiated coverage of ZimVie (ZIMV) with a Buy rating and $16 price target ZimVie is a pure-play medical device company in the dental market with a comprehensive portfolio for tooth replacement and restoration procedures, the analyst tells investors in a research note. The firm says that while management has delivered on its plan to improve the balance sheet and operating profile, the stock trades at a discounted valuation versus peers. It believes ZimVie is poised for continued margin expansion, especially once the market turns positive.